Alpha-MSH blocker for dark spots, always sold beside stronger lighteners; its own effect is untested.
Safety tier
Caution
strict bar
Positive
45%
of 12 reports
Per month
≈ €4–13
estimate
Rank
#14
of 23 supplements
At a glance
Onset
Weeks to months for any visible change
Lasts
Pigment returns over weeks after stopping, faster with sun exposure or shaving
Access
Supplement
Best effects
Gradual lightening of underarm pigmentation in some users (with AHAs and butylresorcinol in the same product)
Downsides
No visible lightening in about a quarter · peeling, heat or burning on application, mainly from the 6% AHA vehicle · burning and itching starting after 1-3 months in a few users
Typical use
Finished products at supplier-recommended levels (a fraction of a percent of a dilute raw-material solution), once or twice daily on the affected area, with daily sunscreen.
Stacked with
Stacked with
Sunscreen: Required for any pigment treatment; also the sensible hedge against the speculative MC1R concern. · tranexamic acid, niacinamide or azelaic acid: Lighteners with human trials; nonapeptide-1 is usually one ingredient among these.
Safety
Watch
Speculative: MC1R signalling does more than make pigment; it also boosts DNA repair of UV damage in melanocytes, and people with loss-of-function MC1R variants have a higher melanoma risk. A topical MC1R antagonist could in principle blunt that protection in treated skin, though no study shows a cosmetic dose does so; sunscreen is part of every brightening routine anyway.
Tier by safety barStrict CautionBalanced CautionEvidence only Caution
Seen harm1 of 3
Mechanism1 of 3
Data gap2 of 3
Silent harm0 of 3
Product0 of 3
Never if
broken, freshly shaved or irritated skin when the product carries acids (the roll-on is 6% AHA) · pregnancy and breastfeeding (no reproductive data)
The only human data are one randomised pilot of 46 people (23 on a multi-active cream containing nonapeptide-1) over about eight months; no study of the peptide alone, no CIR assessment, supplier safety data unpublished. IJDVL 2021 randomized controlled pilot (n=46) ↗
Silent harm 0/3
The harms actually reported (burning, itching, peeling, the one infection) are felt within days and attributable mainly to the acid vehicle; they are obvious and stop with the product. The speculative MC1R concern would be silent if real, but it does not drive the other scores (mechanism 1).
Product 0/3
Bought as finished over-the-counter cosmetics (Minimalist roll-on, brightening serums).
Almost every identifiable report is of one product, Minimalist's Nonapeptide + AHA 6% Underarm Roll-On from India, which also contains glycolic and mandelic acids, salicylic acid, licorice and 4-n-butylresorcinol (a potent tyrosinase inhibitor), so no report can isolate the peptide. Of twelve users who reported on dark underarms, five saw some lightening after weeks of consistent use, three saw none and one could not separate it from a previous roll-on; most of the thread praises it as a deodorant instead. The downsides are the acids': peeling, heat or burning on application, and a few who developed burning and itching after one to three months, plus one report of a painful underarm infection after ten days. Too few and too confounded to judge nonapeptide-1 itself; face serums that list it (usually beside niacinamide, tranexamic acid or arbutin) turned up no first-hand reports that credit it. Felt nothing: ~25% of reports (3/12).
I used minimalist one quite consistently in the start...experienced peeling in my underarms ( it was my first time using a underarm rollon )
but the pigmentation went down quite significantly but not completely.
PositiveTopical · dark underarms
first underarm roll-on; thinks the AHA level is strong for beginners (author since deleted)
Small human studies — no published trial of nonapeptide-1 alone; the only clinical study is a 46-person randomised pilot of a proprietary cream combining it with phenylethyl resorcinol, an aminoethyl phosphinic acid, antioxidants and sunscreen for melasma maintenance, which did not reach significance against sunscreen alone. Otherwise supplier data (about a third less melanin in cell tests) and its use as a reference MC1R antagonist in cell studies
Caveat
Nonapeptide-1 is a synthetic alpha-MSH analogue that occupies the MC1R receptor on pigment cells without switching it on. The idea is preventive, damping new melanin rather than removing existing spots, and the claim rests on supplier cell data. It never appears alone in products people discuss, so whatever lightening users see is shared with acids, resorcinols or tranexamic acid. The roll-on's irritation reports belong to its 6% AHA base. The MC1R-DNA-repair worry is theoretical and unquantified, which is why this is marked mostly-clean rather than clean.
The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.
Report grades
Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.
GlowingPositiveMixedNothingNegativeBad reaction
% positive
The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.
Researcher estimate
No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.
Safety tier
Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.
Safety bar
The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.
Seen harm
Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.
Mechanism
A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.
Data gap
How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.
Silent harm
Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.
Product
The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.
Evidence
The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.
Access
How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.
Price per month
Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.
Dose users report
The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.
Shop trust
Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.
Best value
Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.
Testing
Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.
Added peptide
Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.